ClearPoint Neuro, Inc. filings document the company's medical-device and therapy-enabling business, including operating results for its brain and spine navigation platforms, CNS drug-delivery services, and neurocritical-care portfolio after the completed IRRAS Holdings acquisition. Form 8-K reports furnish quarterly and annual results, Regulation FD investor presentations, acquisition-related financial statements, pro forma combined financial information, and material-event disclosures.
Proxy materials cover governance matters, director voting, executive compensation, pay-versus-performance data, and equity-award disclosures. The filing record also includes material agreements, capital-structure disclosure, shareholder voting matters, and clinical or regulatory disclosures tied to the company's regulated neurosurgical products and partnered biologics programs.
ClearPoint Neuro, Inc. (CLPT) is the subject of an amended ownership statement. As of November 3, 2026, Bigger Capital Fund, LP reported beneficial ownership of 1,707,447 shares, approximately 5.33%; Bigger Capital Fund GP, LLC may be deemed to beneficially own the same position. District 2 Capital Fund LP reported 315,808 shares, approximately 0.99%, and District 2 Capital LP, District 2 GP LLC, District 2 Holdings LLC and Michael Bigger may be deemed to beneficially own that position.
Michael Bigger may be deemed to beneficially own 2,601,255 shares, approximately 8.12%, including 55,000 shares in his IRA, 167,000 shares held by Patricia Winter and 356,000 shares held by his sons. The reporting persons disclaim beneficial ownership of certain shares attributed to other reporting persons: Michael Bigger disclaims ownership of shares held by Ms. Winter and his sons, and the related investment entities disclaim ownership of their respective funds’ shares. Patricia Winter reported 167,000 shares, or 0.52%. The reported percentages use 32,054,268 shares outstanding as of October 21, 2026.
ClearPoint Neuro, Inc. (CLPT) reported third-quarter 2026 revenue of $12.075 million, up 36% from $8.861 million a year earlier, while net loss widened to $7.460 million from $5.891 million. Product revenue was $7.891 million and service and other revenue was $4.184 million. Growth included higher neurosurgery navigation and therapy sales, particularly IRRAflow products, and services at ClearPoint Advanced Laboratories. Gross margin was 58%, compared with 63% a year earlier.
For the nine months ended September 30, 2026, revenue was $35.083 million versus $26.561 million, net loss was $28.349 million versus $17.754 million, and operating cash use was $20.094 million versus $11.845 million. Cash and cash equivalents were $46.184 million as of September 30, 2026; management said its existing cash and cash equivalents were sufficient to support operations and obligations for at least the next twelve months from issuance of the financial statements.
During the quarter, the company sold 1,530,000 common shares through its ATM program for $22.0 million in net proceeds; $27.5 million remained available for sale as of September 30, 2026. Long-term notes payable, net, were $50.840 million, and the notes' effective interest rate was 11.3% at quarter-end. Revenue participation payments to the note investor begin in the first fiscal quarter of 2027.
ClearPoint Neuro, Inc. (CLPT) reported third-quarter 2026 revenue of $12.1 million, up 36% year over year. Neurosurgery navigation and therapy revenue increased 59% to $5.4 million, biologics and drug delivery revenue rose 11% to $4.9 million, and capital equipment and software revenue increased 68% to $1.7 million. The navigation and therapy increase was primarily driven by IRRAflow sales following the company’s acquisition of IRRAS in the fourth quarter of 2025.
Gross margin was 58%, compared with 63% in the prior-year quarter. Operating expenses rose 23% to $13.4 million, mainly driven by the November 2025 IRRAS acquisition and higher personnel, occupancy and travel costs. Net loss was $7.460 million, compared with $5.891 million. Cash and cash equivalents were $46.2 million as of September 30, 2026, while net cash used in operating activities for the nine months ended September 30, 2026 was $20.094 million. The company received $22.0 million in net proceeds from its at-the-market equity offering program and estimates 2026 revenue between $48.0 million and $50.0 million.
ClearPoint Neuro, Inc. director Timothy T. Richards received 319 shares of common stock on October 1, 2026, as payment of fees owed under the company’s Seventh Amended and Restated 2013 Incentive Compensation Plan and Non-Employee Director Compensation Plan. The shares were issued at the common stock’s September 30, 2026 closing price of $12.21 per share. His reported direct holdings following the issuance were 87,863 shares.
ClearPoint Neuro, Inc. director R. John Fletcher acquired 993 shares of common stock on October 1, 2026, in payment of fees owed under the company’s Non-Employee Director Compensation Plan. The shares were issued under the Seventh Amended and Restated 2013 Incentive Compensation Plan at the September 30, 2026 closing price of $12.21 per share. Fletcher directly held 132,004 shares after the transaction. No Rule 10b5-1 plan is reported.
ClearPoint Neuro, Inc. (CLPT) CEO and President Joseph Burnett exercised 12,517 stock options on September 2, 2026 at an exercise price of $3.47 per share, paying the exercise price in cash. He received 12,517 shares of common stock and, according to the company disclosure, no shares were sold in connection with this transaction.
After the exercise, Burnett holds 130,720 shares of ClearPoint Neuro common stock directly and 191,388 shares indirectly through the Joseph M. Burnett Trust dated October 20, 2022, where he is trustee. The options exercised were part of a grant dated August 15, 2019 that vests over three years.
ClearPoint Neuro, Inc. has a Schedule 13G/A filed by MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman reporting their ownership of the company’s common stock. The reporting persons collectively beneficially own 2,375,861 shares of common stock, representing 7.8% of the outstanding class as of June 30, 2026, based on 30,504,227 shares outstanding as of July 27, 2026.
The reporting persons report 0 shares with sole voting or dispositive power and 2,375,861 shares with shared voting and shared dispositive power. The amendment is signed by Michael A. Kaufman in his capacity as managing member and individual reporting person.
ClearPoint Neuro, Inc. shareholders led by Bigger Capital Fund, LP and affiliated entities filed an amended Schedule 13G reporting their beneficial ownership of the company’s common stock. As of August 4, 2026, Bigger Capital beneficially owned 1,405,284 shares of common stock, and its general partner Bigger Capital Fund GP, LLC may be deemed to beneficially own the same amount, representing approximately 4.60% of the class.
District 2 Capital Fund LP beneficially owned 295,196 shares, and related District 2 entities may be deemed to beneficially own that stake, representing 0.96% of outstanding shares. Michael Bigger, through his roles with Bigger GP and District 2 Holdings and his personal and family holdings, may be deemed to beneficially own 2,272,980 shares, or approximately 7.45% of the outstanding common stock, while Patricia Winter holds 167,000 shares, or 0.54%. These percentages are based on 30,504,227 shares outstanding as of July 27, 2026; the filing includes customary disclaimers of beneficial ownership among the reporting persons.
ClearPoint Neuro, Inc. reported Q2 2026 total revenue of $10.9 million, up from $9.2 million in Q2 2025, and six‑month revenue of $23.0 million versus $17.7 million a year earlier. Growth was driven by neurosurgery navigation and therapy revenue of $5.6 million, up 62%, and capital equipment and software revenue of $1.3 million.
Biologics and drug delivery revenue was $4.0 million, down from $4.7 million due to a large prior‑year order that did not repeat. Gross profit was $6.7 million with a 62% gross margin. Operating loss widened to $10.2 million, and net loss to $11.3 million, or $(0.38) per share, as research and development, sales and marketing, and general and administrative expenses all increased.
At June 30, 2026, cash and cash equivalents were $29.4 million, total assets $86.7 million, and long‑term notes payable had a carrying amount of $50.2 million with an effective interest rate of 11.3%. The company recorded net cash used in operating activities of $15.0 million for the first half of 2026 and concluded its existing cash and cash equivalents are sufficient to support operations and meet obligations for at least the next twelve months from the date of issuance of these financial statements.
ClearPoint Neuro reported second quarter 2026 revenue of $10.9 million, up 18% from $9.2 million, driven by strong growth in neurosurgery navigation and therapy, which rose 62% to $5.6 million, and capital equipment and software, up 24% to $1.3 million. Biologics and drug delivery revenue declined 15% to $4.0 million as large prior-year trial-initiation orders did not repeat, though preclinical service revenue grew. Gross margin improved to 62%.
Operating expenses increased to $17.0 million, reflecting the IRRAflow acquisition and expansion of clinical and sales teams, contributing to an operating loss and a basic and diluted net loss per share of $0.38 versus $0.21 a year earlier. Cash and cash equivalents were $29.4 million at June 30, 2026, down from $45.9 million at year-end, mainly due to $15.0 million used in operating activities and $2.0 million of tax payments related to equity awards. Management now expects 2026 revenue between $48.0 million and $52.0 million.
The company highlighted multiple biopharma partners receiving positive FDA feedback on potential BLA submissions and expects 10–15 clinical trials using its technology to be enrolling in the next 18 months, with roughly 10 data readouts. ClearPoint took possession of its ClearPoint Advanced Laboratories facility, signed initial preclinical statements of work including its first GLP study, and announced a 10-year focused ultrasound drug-delivery partnership with the SONOCARE Lab in South Korea, while advancing its robotic platform and Harmony 1.0 software to expand capacity ahead of potential commercial cell and gene therapy launches around 2027.